Evidence map›Paper›PMID 39136501›Full record

ReviewCurrent Alzheimer research2024

Advances in Developing Small Molecule Drugs for Alzheimer's Disease.

Wei Zhang, Liujie Zhang, Mingti Lv, Yun Fu, Xiaowen Meng, Mingyong Wang, Hecheng Wang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current Alzheimer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wei ZhangSchool of Basic Medical Science, Xinxiang Medical University, Xinxiang, China.
Liujie ZhangSchool of Basic Medical Science, Xinxiang Medical University, Xinxiang, China.
Mingti LvSchool of Basic Medical Science, Xinxiang Medical University, Xinxiang, China.
Yun FuSchool of Basic Medical Science, Xinxiang Medical University, Xinxiang, China.
Xiaowen MengSchool of Basic Medical Science, Xinxiang Medical University, Xinxiang, China.
Mingyong WangSchool of Medical Technology, Xinxiang Medical University, Xinxiang, China.
Hecheng WangSchool of Basic Medical Science, Xinxiang Medical University, Xinxiang, China.

Funding

National Natural Science Foundation of China (82271860)Natural Science Foundation of Henan Province 222300420515Xinxiang Medical University YJSCX202208Z
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most common type of dementia among middle-aged and elderly individuals. Accelerating the prevention and treatment of AD has become an urgent problem. New technology including Computer-aided drug design (CADD) can effectively reduce the medication cost for patients with AD, reduce the cost of living, and improve the quality of life of patients, providing new ideas for treating AD. This paper reviews the pathogenesis of AD, the latest developments in CADD and other small-molecule docking technologies for drug discovery and development; the current research status of small-molecule compounds for AD at home and abroad from the perspective of drug action targets; the future of AD drug development.

Indexed as

Alzheimer DiseaseAnimalsComputer-Aided DesignDrug DesignDrug DevelopmentDrug DiscoveryHumansAlzheime's diseasecomputer-aided drug design targetsforkhead box protein O1pathogenesis.small molecule drugsβ-amyloid

Identifiers

PMID39136501

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.